SCHEMBL7180157

SCHEMBL7180157

Brc1cccc(/C=C/COC2CCCCO2)c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
OPRM1 P35372 1/20 0.38
KDM4C Q9H3R0 1/20 0.38
CA2 P00918 4/20 0.36
CA1 P00915 3/20 0.36
HSD17B3 P37058 1/20 0.35
SLC6A19 Q695T7 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
PKM P14618 1/20 0.34
HPGD P15428 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
METAP2 P50579 1/20 0.34
PTAFR P25105 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180161 1.00 ALDH1A1 (0.40) ALDH1A1OPRM1KDM4CCA2CA1
SCHEMBL12828031 0.86 MEN1 (0.41) ALDH1A1KDM4CCA2CA1HSD17B3
SCHEMBL9738262 0.84 OPRM1 (0.39) ALDH1A1OPRM1KDM4CNPC1RAB9A
SCHEMBL9738265 0.84 OPRM1 (0.39) ALDH1A1OPRM1KDM4CNPC1RAB9A
SCHEMBL17844772 0.84 OPRM1 (0.52) ALDH1A1OPRM1KDM4CNPC1RAB9A
SCHEMBL17844735 0.84 OPRM1 (0.52) ALDH1A1OPRM1KDM4CNPC1RAB9A
SCHEMBL25166444 0.80 ALDH1A1 (0.50) ALDH1A1HPGDMEN1KMT2AL3MBTL1
SCHEMBL31419830 0.80 ALDH1A1 (0.50) ALDH1A1OPRM1KDM4CMEN1KMT2A
SCHEMBL3393686 0.79 CHRNA7 (0.49) ALDH1A1KDM4CNPC1RAB9AHPGD
SCHEMBL29865973 0.75 CA2 (0.45) ALDH1A1KDM4CCA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268494-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS Merck Frosst Canada & Co. (CA) 2003-01-02 EP disclosed
US-6498151-B2 PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS MERCK FROSST CANADA & CO. (CA) 2002-12-24 US disclosed
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors MERCK FROSST CANADA LTD. (CA) 2002-07-11 US disclosed
WO-2001070753-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors PTPRF, PTPRS, PTPRO ALDH1A1 312/4885OPRM1 4651/4885KDM4C 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.